William De Nardo

Jan 14, 2025 | biorxiv.org | Qing Zhao |William De Nardo |Ruoyu Wang |Yi Zhong

AbstractMetabolic dysfunction-associated steatotic liver disease (MASLD) is generally asymptomatic in the early stages but, without appropriate intervention, it can progress to severe liver morbidities. To elucidate the molecular mechanisms of early development of MASLD, we performed transcriptomic analysis on liver biopsies and metabolomic analysis on liver and plasma samples from 109 obese individuals with no liver pathology or early stages of MASLD.

Dec 11, 2024 | cell.com | Marziyeh Anari |Hamzeh Karimkhanloo |Shuai Nie |Li Dong |Gio Fidelito |Jacqueline A. Bayliss | +11 more

Keywords lipoprotein lipase very low-density lipoprotein tissue communication ceramide phospholipid lipid metabolism Research topic(s) CP: Metabolism Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined as steatotic liver disease in the presence of one or more cardiometabolic risk factors, including obesity, type 2 diabetes, and dyslipidemia.1 Metabolic dysfunction-associated steatohepatitis (MASH) is the more severe form of MASLD, and in addition to excess...